Are ENLV insiders buying or selling?

In the last 90 days, Enlivex (ENLV) had 10 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own ENLV?

See every hedge fund and asset manager holding Enlivex (ENLV).

How much of ENLV trades in dark pools?

Track Enlivex (ENLV) dark pool activity and off-exchange block trades.

Enlivex (ENLV) — Hedge Funds Added +$2M Q-o-Q

Also trades as: ENLV.TA (TLV) · $vol 0M

$0.72

-0.00 (-0.37%)

Weekly Expected Move ±6.1%

$1 $1 $1 $1 $1

NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 29 · $17.4M mcap · 24M float · 2.24% daily turnover · Short 31% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest

Smart Money Score

Moderate 50

Insider—

Congress—

ETF Holdings—

Key Statistics

Market Cap$17.4M

52W Range0.66-2.1

Volume112,374

Avg Volume540,590

Beta1.49

Dividend—

Analyst Ratings

3 Buy 1 Hold 0 Sell

Consensus Buy

Company Info

CEOOren Hershkovitz

Employees71

SectorHealthcare

IndustryBiotechnology

IPO Date2014-07-31

Websiteenlivex.com

14 Einstein Street
Ness Ziona 7403618
IL

972 8 662 3301

About Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Latest News

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Bullish GlobeNewsWire-CompanyAnnouncements · 3w ago

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

Bullish GlobeNewsWire-CompanyAnnouncements · 3w ago

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

GlobeNewsWire-CompanyAnnouncements · 4w ago

Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

GlobeNewsWire-CompanyAnnouncements · 4w ago